The Life Sciences team advised Sweden-based Olink Holding AB (publ) (Nasdaq: OLK) on its initial public offering of 13,235,294 common shares in the form of American Depositary Shares (ADSs) at a price to the public of $20 per share in the largest U.S. IPO of a European life sciences company since 2019, according to data from PitchBook. An additional 7,058,822 ADSs were sold by selling shareholders in the offering, including 2,647,058 ADS sold through the exercise in full of the underwriters’ over-allotment option. The gross proceeds of the offering to the Company, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, were approximately $264.7 million.
Headquartered in Uppsala, Sweden, Olink provides a platform of proteomics-related products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science.
The Goodwin team was led by Kristopher Brown and Stephanie Richards and included Humza Bokhari, Hayden Hutto, and Eugenia Sims. The team also included Lily Wound, Janet Andolina, Sarah Bock, Cathy McCarty, Stephanie Philbin, Gretchen Scott, and Ettore Santucci with assistance from former Goodwin lawyers Amoli Pandya and Jennifer Wong.
For more details, read the press release.